Under the terms of the Collaboration Agreement, GSK will pay the Company up to $545.0 million, of which $45.0 million and $40.0 million was received and recognized by the Company in the second quarter of 2012 and 2011, respectively
对ezogabine疗效有兴趣的读者不妨读读Chicago Tribune的这篇文章。 网页链接
所以升级版本的Potiga如果可以上市,估计销量在$100M - $150M也算合理。考虑到XENE现在的市值,难怪有人把XENE称为下一个 $Sage Therapeutics, Inc. (SAGE)$